
    
      This is a single arm, phase II study. Advanced BTC patients who have been previously treated
      with immunotherapy in either the 2nd or 3rd line will be enrolled.

      Patients will be treated with AZD6738 and Durvalumab combination.

      One cycle consists of 4weeks. Response evaluation will be done every 8 weeks (every 2 cycles)
      of treatment

        1. Tumor biopsy is mandatory: screening, after 8weeks (1st-response evaluation), at disease
           progression (PD)

        2. blood sampling for biomarker study is mandatory: every cycles

        3. To evaluate the metabolic changes by AZD6738 and Durvalumab combination : 18 F-FDG PET
           is mandatory : screening, after 8 weeks (1st-response evaluation)
    
  